New hope for tough lung cancer: drug targets Cancer's repair system

NCT ID NCT05450965

Recruiting now Disease control Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 19, 2026 · Updated 16 times

Summary

This study tests a drug called onvansertib in about 37 people with small cell lung cancer that did not respond to or could not tolerate chemotherapy. Onvansertib blocks a protein that cancer cells need to repair themselves, aiming to shrink tumors. The main goal is to see how many patients have their tumors shrink or disappear.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

UPMC Hillman Cancer Center
ACTIVE_NOT_RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
University of Maryland Greenebaum Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21201, United States

Contact

Contact

Conditions

Explore the condition pages connected to this study.

SMALL CELL LUNG CANCER SMALL CELL LUNG CARCINOMA